Citigroup
RNAM

Citigroup’s Avidity Biosciences RNAM Stock Holding History

Citigroup’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$8.71K – 6401
2025
Q3 		$8.71K Buy
+200
New +$8.09K ﹤0.01% 5068
2024
Q4 		– Sell
-27,000
Closed -$1.24M – 5930
2024
Q3 		$1.24M Buy
+27,000
New +$1.17M ﹤0.01% 3089

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Citigroup's RNAM Position: Q1 2026 in Review

Citigroup sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 467,686 shares — an estimated $33.7M sold.

Citigroup first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $33.7M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Citigroup reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 467,686 Avidity Biosciences shares in Q1 2026, an estimated $33.7M.
  • Citigroup first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
  • Citigroup's Avidity Biosciences position peaked at $33.7M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.